Click here to get full coverage on Will AVTX stock split again soon - Quarterly Growth Report & Expert Approved Momentum Ideas - Newser

Will AVTX stock split again soon - Quarterly Growth Report & Expert Approved Momentum Ideas  Newser

Will AVTX stock split again soon - Quarterly Growth Report & Expert Approved Momentum Ideas - Newser

Click here to get full coverage on $AVTX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative

$AVTX stock is down 13% today. Here's what we see in our data.  Quiver Quantitative

$AVTX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Yahoo Finance

Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)  Yahoo Finance

Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Yahoo Finance

Click here to get full coverage on Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView

Avalo Therapeutics, Inc. Updates Investor Presentation  TradingView

Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView

Click here to get full coverage on AVTX-009 Completes Enrollment in HS Phase 2 Trial - Dermatology Times

AVTX-009 Completes Enrollment in HS Phase 2 Trial  Dermatology Times

AVTX-009 Completes Enrollment in HS Phase 2 Trial - Dermatology Times

Click here to get full coverage on BTIG Reiterates Avalo Therapeutics (AVTX) Buy Recommendation - Nasdaq

BTIG Reiterates Avalo Therapeutics (AVTX) Buy Recommendation  Nasdaq

BTIG Reiterates Avalo Therapeutics (AVTX) Buy Recommendation - Nasdaq

Click here to get full coverage on Avalo Therapeutics (Nasdaq: AVTX) grants 114,000 inducement stock options for hires - Stock Titan

Avalo Therapeutics (Nasdaq: AVTX) grants 114,000 inducement stock options for hires  Stock Titan

Avalo Therapeutics (Nasdaq: AVTX) grants 114,000 inducement stock options for hires - Stock Titan

Click here to get full coverage on Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely? - simplywall.st

Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely?  simplywall.st

Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely? - simplywall.st

Click here to get full coverage on Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009’s LOTUS Results (NASDAQ:AVTX) - Seeking Alpha

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009’s LOTUS Results (NASDAQ:AVTX)  Seeking Alpha

Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009’s LOTUS Results (NASDAQ:AVTX) - Seeking Alpha

Click here to get full coverage on Avalo Completes Enrollment for Phase 2 LOTUS Trial - TipRanks

Avalo Completes Enrollment for Phase 2 LOTUS Trial  TipRanks

Avalo Completes Enrollment for Phase 2 LOTUS Trial - TipRanks

Click here to get full coverage on Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates  GlobeNewswire

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire

Click here to get full coverage on We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth - Yahoo Finance

We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth  Yahoo Finance

We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth - Yahoo Finance

Click here to get full coverage on Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains - simplywall.st

Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains  simplywall.st

Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains - simplywall.st

Click here to get full coverage on New Analyst Forecast: $AVTX Given $25.0 Price Target | AVTX Stock News - Quiver Quantitative

New Analyst Forecast: $AVTX Given $25.0 Price Target | AVTX Stock News  Quiver Quantitative

New Analyst Forecast: $AVTX Given $25.0 Price Target | AVTX Stock News - Quiver Quantitative

Click here to get full coverage on Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa - Nasdaq

Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa  Nasdaq

Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa - Nasdaq

Click here to get full coverage on Avalo Therapeutics Announces Completion of Enrollment in - GlobeNewswire

Avalo Therapeutics Announces Completion of Enrollment in  GlobeNewswire

Avalo Therapeutics Announces Completion of Enrollment in - GlobeNewswire

Click here to get full coverage on Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Yahoo Finance

Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX)  Yahoo Finance

Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $AVTX Given $40.0 Price Target | AVTX Stock News - Quiver Quantitative

New Analyst Forecast: $AVTX Given $40.0 Price Target | AVTX Stock News  Quiver Quantitative

New Analyst Forecast: $AVTX Given $40.0 Price Target | AVTX Stock News - Quiver Quantitative

Click here to get full coverage on Former Longboard $2.6B Deal Architect Joins Avalo Therapeutics as CBO Ahead of Key Trial Results - Stock Titan

Former Longboard $2.6B Deal Architect Joins Avalo Therapeutics as CBO Ahead of Key Trial Results  Stock Titan

Former Longboard $2.6B Deal Architect Joins Avalo Therapeutics as CBO Ahead of Key Trial Results - Stock Titan

Click here to get full coverage on Avalo Therapeutics Director Makes Significant Stock Sale! - TipRanks

Avalo Therapeutics Director Makes Significant Stock Sale!  TipRanks

Avalo Therapeutics Director Makes Significant Stock Sale! - TipRanks

Click here to get full coverage on Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug - Stocktwits

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug  Stocktwits

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug - Stocktwits

Click here to get full coverage on Shareholders in Avantium (AMS:AVTX) are in the red if they invested five years ago - Yahoo Finance

Shareholders in Avantium (AMS:AVTX) are in the red if they invested five years ago  Yahoo Finance

Shareholders in Avantium (AMS:AVTX) are in the red if they invested five years ago - Yahoo Finance

Click here to get full coverage on Avalo Therapeutics (Nasdaq: AVTX) completes Phase 2 HS trial enrollment with 250 patients - Stock Titan

Avalo Therapeutics (Nasdaq: AVTX) completes Phase 2 HS trial enrollment with 250 patients  Stock Titan

Avalo Therapeutics (Nasdaq: AVTX) completes Phase 2 HS trial enrollment with 250 patients - Stock Titan

Click here to get full coverage on Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates  GlobeNewswire

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire

Click here to get full coverage on Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewswire

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors  GlobeNewswire

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewswire

Click here to get full coverage on Cowen initiates Avalo Therapeutics stock with Buy rating - Investing.com

Cowen initiates Avalo Therapeutics stock with Buy rating  Investing.com

Cowen initiates Avalo Therapeutics stock with Buy rating - Investing.com

Click here to get full coverage on H.C. Wainwright raises Avalo Therapeutics stock price target to $25 on IL-1 pathway validation - Investing.com

H.C. Wainwright raises Avalo Therapeutics stock price target to $25 on IL-1 pathway validation  Investing.com

H.C. Wainwright raises Avalo Therapeutics stock price target to $25 on IL-1 pathway validation - Investing.com

Click here to get full coverage on Avalo (AVTX) Advances with Completion of LOTUS Trial Enrollment - GuruFocus

Avalo (AVTX) Advances with Completion of LOTUS Trial Enrollment  GuruFocus

Avalo (AVTX) Advances with Completion of LOTUS Trial Enrollment - GuruFocus

Click here to get full coverage on Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study - TipRanks

Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study  TipRanks

Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study - TipRanks

Click here to get full coverage on Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Avalo Therapeutics to Participate in Upcoming Investor Conferences  GlobeNewswire

Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Click here to get full coverage on Avalo Therapeutics Completes Enrollment in Phase 2 LOTUS Trial - TradingView

Avalo Therapeutics Completes Enrollment in Phase 2 LOTUS Trial  TradingView

Avalo Therapeutics Completes Enrollment in Phase 2 LOTUS Trial - TradingView

Click here to get full coverage on Avalo Therapeutics appoints former Longboard CEO Kevin Lind to board - Investing.com

Avalo Therapeutics appoints former Longboard CEO Kevin Lind to board  Investing.com

Avalo Therapeutics appoints former Longboard CEO Kevin Lind to board - Investing.com

Click here to get full coverage on Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Benzinga

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket  Benzinga

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Benzinga

Click here to get full coverage on Avantium (AMS:AVTX) shareholders are up 11% this past week, but still in the red over the last five years - simplywall.st

Avantium (AMS:AVTX) shareholders are up 11% this past week, but still in the red over the last five years  simplywall.st

Avantium (AMS:AVTX) shareholders are up 11% this past week, but still in the red over the last five years - simplywall.st

Click here to get full coverage on BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40  富途牛牛

BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

Click here to get full coverage on Avalo Therapeutics Strengthens Leadership with Key Appointments - TipRanks

Avalo Therapeutics Strengthens Leadership with Key Appointments  TipRanks

Avalo Therapeutics Strengthens Leadership with Key Appointments - TipRanks

Click here to get full coverage on Does Avantium’s €65 Million Capital Raise and Narrowed Losses Reshape Its Transition Narrative (ENXTAM:AVTX)? - simplywall.st

Does Avantium’s €65 Million Capital Raise and Narrowed Losses Reshape Its Transition Narrative (ENXTAM:AVTX)?  simplywall.st

Does Avantium’s €65 Million Capital Raise and Narrowed Losses Reshape Its Transition Narrative (ENXTAM:AVTX)? - simplywall.st

Click here to get full coverage on Need To Know: The Consensus Just Cut Its Avantium N.V. (AMS:AVTX) Estimates For 2025 - simplywall.st

Need To Know: The Consensus Just Cut Its Avantium N.V. (AMS:AVTX) Estimates For 2025  simplywall.st

Need To Know: The Consensus Just Cut Its Avantium N.V. (AMS:AVTX) Estimates For 2025 - simplywall.st

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - Nasdaq

Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk  Nasdaq

Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk - Nasdaq

Click here to get full coverage on Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform - Investing.com

Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform  Investing.com

Oppenheimer reiterates Avalo Therapeutics stock rating at Outperform - Investing.com

Click here to get full coverage on Avalo Completes Enrollment for Phase 2 LOTUS Trial - MSN

Avalo Completes Enrollment for Phase 2 LOTUS Trial  MSN

Avalo Completes Enrollment for Phase 2 LOTUS Trial - MSN

Click here to get full coverage on Avalo Therapeutics Reports Business Updates and Financial Results for 2024, Highlights Phase 2 LOTUS Trial Progress for AVTX-009 in Hidradenitis Suppurativa - Nasdaq

Avalo Therapeutics Reports Business Updates and Financial Results for 2024, Highlights Phase 2 LOTUS Trial Progress for AVTX-009 in Hidradenitis Suppurativa  Nasdaq

Avalo Therapeutics Reports Business Updates and Financial Results for 2024, Highlights Phase 2 LOTUS Trial Progress for AVTX-009 in Hidradenitis Suppurativa - Nasdaq

Click here to get full coverage on Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board  GlobeNewswire

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - GlobeNewswire

Click here to get full coverage on Avantium First Half 2025 Earnings: €1.08 loss per share (vs €1.90 loss in 1H 2024) - simplywall.st

Avantium First Half 2025 Earnings: €1.08 loss per share (vs €1.90 loss in 1H 2024)  simplywall.st

Avantium First Half 2025 Earnings: €1.08 loss per share (vs €1.90 loss in 1H 2024) - simplywall.st

Click here to get full coverage on Avalo Therapeutics expands leadership with two senior appointments - Investing.com

Avalo Therapeutics expands leadership with two senior appointments  Investing.com

Avalo Therapeutics expands leadership with two senior appointments - Investing.com

Click here to get full coverage on Avalo Therapeutics Reports Q3 2025 Financial Results - TipRanks

Avalo Therapeutics Reports Q3 2025 Financial Results  TipRanks

Avalo Therapeutics Reports Q3 2025 Financial Results - TipRanks

Click here to get full coverage on First patient dosed in phase 2 trial evaluating AVTX-009 for hidradenitis suppurativa - Healio

First patient dosed in phase 2 trial evaluating AVTX-009 for hidradenitis suppurativa  Healio

First patient dosed in phase 2 trial evaluating AVTX-009 for hidradenitis suppurativa - Healio

Click here to get full coverage on Avalo Therapeutics (AVTX) Stock Forecast and Price Target 2025 - MarketBeat

Avalo Therapeutics (AVTX) Stock Forecast and Price Target 2025  MarketBeat

Avalo Therapeutics (AVTX) Stock Forecast and Price Target 2025 - MarketBeat

Click here to get full coverage on Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug - Fierce Biotech

Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug  Fierce Biotech

Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug - Fierce Biotech

Click here to get full coverage on Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why - Yahoo Finance

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why  Yahoo Finance

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why - Yahoo Finance

Click here to get full coverage on Avalo drops three rare disease assets amid ongoing challenges - Pharmaceutical Technology

Avalo drops three rare disease assets amid ongoing challenges  Pharmaceutical Technology

Avalo drops three rare disease assets amid ongoing challenges - Pharmaceutical Technology

Click here to get full coverage on Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89% - Yahoo Finance

Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%  Yahoo Finance

Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89% - Yahoo Finance

Click here to get full coverage on Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs - Nasdaq

Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs  Nasdaq

Avalo (AVTX) Up 45% on Deal to Divest Certain Pipeline Drugs - Nasdaq

Click here to get full coverage on Avalo Therapeutics appoints Dr. Rita Jain to board of directors By Investing.com - Investing.com UK

Avalo Therapeutics appoints Dr. Rita Jain to board of directors By Investing.com  Investing.com UK

Avalo Therapeutics appoints Dr. Rita Jain to board of directors By Investing.com - Investing.com UK

Click here to get full coverage on Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot - BioSpace

Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot  BioSpace

Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot - BioSpace

Click here to get full coverage on Avalo Therapeutics Closes $69.4 Million Financing - citybiz

Avalo Therapeutics Closes $69.4 Million Financing  citybiz

Avalo Therapeutics Closes $69.4 Million Financing - citybiz

Click here to get full coverage on Is Avalo Therapeutics (AVTX) A Hidden Gem or A Value Trap? - Yahoo Finance

Is Avalo Therapeutics (AVTX) A Hidden Gem or A Value Trap?  Yahoo Finance

Is Avalo Therapeutics (AVTX) A Hidden Gem or A Value Trap? - Yahoo Finance

Click here to get full coverage on Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million - GlobeNewswire

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million  GlobeNewswire

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million - GlobeNewswire

Click here to get full coverage on Avalo Therapeutics (AVTX) - Zacks Investment Research

Avalo Therapeutics (AVTX)  Zacks Investment Research

Avalo Therapeutics (AVTX) - Zacks Investment Research

Click here to get full coverage on AVTX Stock Price and Chart — NASDAQ:AVTX - TradingView

AVTX Stock Price and Chart — NASDAQ:AVTX  TradingView

AVTX Stock Price and Chart — NASDAQ:AVTX - TradingView

Click here to get full coverage on Avalo’s asthma therapy trial fails to meet primary endpoint - Clinical Trials Arena

Avalo’s asthma therapy trial fails to meet primary endpoint  Clinical Trials Arena

Avalo’s asthma therapy trial fails to meet primary endpoint - Clinical Trials Arena

Click here to get full coverage on Avalo looks to LIGHT as lead asset fails phase 2 asthma trial, dampening stock - Fierce Biotech

Avalo looks to LIGHT as lead asset fails phase 2 asthma trial, dampening stock  Fierce Biotech

Avalo looks to LIGHT as lead asset fails phase 2 asthma trial, dampening stock - Fierce Biotech

Click here to get full coverage on Avalo's spiral deepens amid default, spurring attempt to sell off assets - Fierce Biotech

Avalo's spiral deepens amid default, spurring attempt to sell off assets  Fierce Biotech

Avalo's spiral deepens amid default, spurring attempt to sell off assets - Fierce Biotech

Click here to get full coverage on Shareholders Will Probably Hold Off On Increasing Avantium N.V.'s (AMS:AVTX) CEO Compensation For The Time Being - Yahoo Finance

Shareholders Will Probably Hold Off On Increasing Avantium N.V.'s (AMS:AVTX) CEO Compensation For The Time Being  Yahoo Finance

Shareholders Will Probably Hold Off On Increasing Avantium N.V.'s (AMS:AVTX) CEO Compensation For The Time Being - Yahoo Finance

Click here to get full coverage on Avalo adjusts almost entire pipeline weeks after CEO, CFO say sayonara - Fierce Biotech

Avalo adjusts almost entire pipeline weeks after CEO, CFO say sayonara  Fierce Biotech

AVTX

Price Chart

Key Statistics

Technicals

About AVTX

Latest News

Will AVTX stock split again soon - Quarterly Growth Report & Expert Approved Momentum Ideas - Newser

$AVTX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative

Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers